Guilin Sanjin Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Guilin Sanjin Pharmaceutical Co Ltd cash flow-to-debt ratio. Guilin Sanjin Pharmaceutical Co Ltd (002275) has a Cash Flow-to-Debt Ratio of 0.11x as of September 2025, meaning its operating cash flow of CN¥117.62 Million could theoretically repay 0% of its total liabilities (CN¥1.05 Billion) in one year. Check Guilin Sanjin Pharmaceutical Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)
Cash flow-to-debt ratio of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024. Historical debt coverage capacity for Guilin Sanjin Pharmaceutical Co Ltd across 19 annual periods. Check Guilin Sanjin Pharmaceutical Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Guilin Sanjin Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2006–2024)
Guilin Sanjin Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2006 to 2024. Year-by-year debt coverage analysis for Guilin Sanjin Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see how efficiently does Guilin Sanjin Pharmaceutical Co Ltd generate cash.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.48x | CN¥588.33 Million | CN¥1.22 Billion | ▼ -1.9% |
| 2023 | 0.49x | CN¥549.25 Million | CN¥1.12 Billion | ▲ +6.9% |
| 2022 | 0.46x | CN¥528.67 Million | CN¥1.15 Billion | ▲ +40.6% |
| 2021 | 0.33x | CN¥410.24 Million | CN¥1.26 Billion | ▼ -49.6% |
| 2020 | 0.65x | CN¥597.99 Million | CN¥923.27 Million | ▼ -17.0% |
| 2019 | 0.78x | CN¥468.29 Million | CN¥600.18 Million | ▼ -15.2% |
| 2018 | 0.92x | CN¥551.73 Million | CN¥599.47 Million | ▲ +36.6% |
| 2017 | 0.67x | CN¥387.82 Million | CN¥575.65 Million | ▼ -44.2% |
| 2016 | 1.21x | CN¥536.85 Million | CN¥444.26 Million | ▲ +26.3% |
| 2015 | 0.96x | CN¥398.50 Million | CN¥416.59 Million | ▲ +11.7% |
| 2014 | 0.86x | CN¥396.53 Million | CN¥463.07 Million | ▲ +32.5% |
| 2013 | 0.65x | CN¥314.16 Million | CN¥486.11 Million | ▼ -13.0% |
| 2012 | 0.74x | CN¥302.59 Million | CN¥407.26 Million | ▼ -52.5% |
| 2011 | 1.56x | CN¥341.05 Million | CN¥218.18 Million | ▼ -0.6% |
| 2010 | 1.57x | CN¥285.49 Million | CN¥181.47 Million | ▲ +20.8% |
| 2009 | 1.30x | CN¥363.29 Million | CN¥279.00 Million | ▲ +158.2% |
| 2008 | 0.50x | CN¥190.97 Million | CN¥378.65 Million | ▲ +7.2% |
| 2007 | 0.47x | CN¥164.39 Million | CN¥349.58 Million | ▼ -55.8% |
| 2006 | 1.06x | CN¥217.67 Million | CN¥204.48 Million | — |